Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications

Clinical Schizophrenia and Related Psychoses

Volumn 4, Issue 3, 2010, Pages 161-168

  Jerrell, Jeanette M ^a   McIntyre, Roger S ^b   Tripathi, Avnish ^c  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antipsychotic agents; Costs of care; Hypertension; Metabolic conditions; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; COST BENEFIT ANALYSIS; DRUG COST; DYSLIPIDEMIA; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL COST; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAID; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; UNITED STATES;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HEALTH CARE COSTS; HUMANS; HYPERTENSION; INCIDENCE; MALE; METABOLIC DISEASES; MIDDLE AGED; OBESITY; ODDS RATIO; PRESCRIPTION FEES; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; SOUTH CAROLINA; YOUNG ADULT;

EID: 77957666970     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.4.3.2     Document Type: Article

References (32)

1. Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004;74(16):1999-2008. (Pubitemid 38210353)
2. Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 2002;71(3):239-257. (Pubitemid 34597188)
3. Adams PF, Marano MA. Current estimates from the National Health Interview Survey, 1994. Vital Health Stat 10 1995;193 Pt 1:1-260.
4. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006;3(2):A42.
5. Hennekens CH. Increasing global burden of cardiovascular disease in general population and patients with schizophrenia. J Clin Psychiatry 2007;68(Suppl 4):4-7. (Pubitemid 46762117)
6. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80(1):19-32. (Pubitemid 41587460)
7. Dixon L, Weiden P, Delanhanty J, Goldberg R, Postrado L, Lucksted A, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000;26(4):903-912.
8. Lieberman JA 3rd. Metabolic changes associated with antipsychotic use. Prim Care Companion J Clin Psychiatry 2004;6 (Suppl 2):8-13.
9. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996;37(1):68-73.
10. Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 2005;118(Suppl 2):15S-22S.
11. Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, et al. What CATIE found: results from the schizophrenia trial. Psychiatr Serv 2008;59(5):500-506.
12. Meyer JM, Davis VG, McEvoy JP, Goff DC, Nasrallah HA, Davis SM, et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res 2008;103(1-3):104-109.
13. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005;62(1):19-28. (Pubitemid 40096067)
14. Caro JJ, Ward A, Levinton C, Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2002;63(12):1135-1139. (Pubitemid 36084058)
15. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002;63(10):920-930.
16. Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002;325(7358):243.
17. Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension. Arch Gen Psychiatry 2001;58(12):1172-1176. (Pubitemid 33121510)
18. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159(4):561-566. (Pubitemid 34274937)
19. Kornegay CJ, Vasilakis-Scaramozza C, Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry 2002;63(9):758-762.
20. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004;161(9):1709-1711.
21. Leslie DL, Rosenheck RA. Pharmacotherapy and health care costs among patients with schizophrenia and newly diagnosed diabetes. Psychiatr Serv 2005;56(7):803-809. (Pubitemid 40967456)
22. Nasrallah HA. Pharmacoeconomic implications of adverse effects during antipsychotic drug therapy. Am J Health Syst Pharm 2002;59(22 Suppl 8):S16-S21. (Pubitemid 35304083)
23. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, et al. A prospective study of triglyceride level, low density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276(11):882-888. (Pubitemid 26301607)
24. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998;97(11):1029-1036.
25. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287(3):356-359. (Pubitemid 34251969)
26. Covell NH, Finnerty MT, Essock SM. Implications of CATIE for mental health services researchers. Psychiatr Serv 2008;59(5):526-529.
27. McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 2005;66(Suppl 3):28-36. (Pubitemid 40461409)
28. Holmberg SK, Kane C. Health and self-care practices of persons with schizophrenia. Psychiatr Serv 1999;50(6):827-829. (Pubitemid 29258962)
29. Lurie N, Popkin M, Dysken M, Moscovice I, Finch M. Accuracy of diagnosis of schizophrenia in Medicaid claims. Hosp Community Psychiatry 1992;43(1):69-71.
30. Mark TL, Buck JA, Dilonardo JD, Coffey RM, Chalk M. Medicaid expenditures on behavioral health care. Psychiatr Serv 2003;54(2):188-194. (Pubitemid 36752849)
31. Unutzer J, Simon G, Pabiniak C, Bond K, Katon W. The use of administrative data to assess quality of care for bipolar disorders in a large staff model HMO. Gen Hosp Psychiatry 2000;22(1):1-10. (Pubitemid 30129086)
32. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, Hennekens CH, Lambert M, Leucht S, et al. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry 2008;69(4):514-519. (Pubitemid 351792324)